IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

NCT07686380 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

NIH

Sponsor class

Conditions

Recurrent Prostate Cancer
Prostate Cancer

Interventions

DRUG: N-803
DRUG: ETBX-71 Vaccine
RADIATION: 18F-DCFPyL

Sponsor

National Cancer Institute (NCI)